Eurofins CDMO Alphora, a member of the international Eurofins Scientific network, has announced the launch of an AI-powered software platform for high-throughput salt and co-crystal screening. This innovation aims to modernize solid-state research programs within the drug development lifecycle.
Predictive technology through Machine Learning
Developed in partnership with a Canadian university, this machine learning platform accurately predicts salt and co-crystal formation for active pharmaceutical ingredients (APIs) and intermediates.
-
Core benefits: The technology streamlines solid form selection by minimizing trial-and-error experimentation.
-
Economic efficiency: It shortens development timelines and significantly lowers screening costs for clients.
-
User experience: A user-friendly interface empowers clients to make smarter, data-driven decisions more efficiently.
2026 infrastructure expansion plans
In addition to the software launch, Eurofins CDMO Alphora is preparing to commission its new GMP biologics manufacturing facility in Mississauga, Ontario, this spring.
-
Scale: The 50,000-square-foot facility is situated within a larger campus and equipped with 2000L bioreactor systems.
-
Technology: It utilizes single-use technology and is capable of running both fed-batch and perfusion modes.
The integration of advanced AI software and modern manufacturing infrastructure reinforces the company’s strategic vision of providing comprehensive, integrated solutions for the pharmaceutical industry.